Quadrature Capital’s Krystal Biotech KRYS Stock Holding History

Quadrature Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,189	Closed	-$824K	–	1847
2026 Q1	$824K	Buy	+3,189	New	+$849K	0.01%	628

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quadrature Capital's KRYS Position: Q2 2026 in Review

Quadrature Capital sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 3,189 shares — an estimated $824K sold.

Quadrature Capital first reported a position in KRYS in Q1 2026 and held it in 1 quarter. The position peaked at $824K in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Quadrature Capital reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 3,189 Krystal Biotech shares in Q2 2026, an estimated $824K.
Quadrature Capital first reported a position in Krystal Biotech in Q1 2026 and held it in 1 quarter.
Quadrature Capital's Krystal Biotech position peaked at $824K in Q1 2026.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.